Real world effectiveness and safety of oral Janus kinase inhibitor in vitiligo: a retrospective study

Journal of the American Academy of DermatologySeptember 22

n=96

Clinical Summary

View source

What was studied

A single-center retrospective study evaluated real-world effectiveness and safety of oral JAK inhibitors in 96 patients with vitiligo treated for at least 3 months, and used multivariable logistic regression to identify predictors of response.

Key findings

Overall, 55.2% achieved >25% repigmentation; 9.4% achieved marked repigmentation (≥76%), and 86/96 (89.6%) had some degree of repigmentation. No severe adverse events were observed; age, prior phototherapy, and treatment >6 months independently predicted response.

Study limitations

Single-center study with limited patients.

Clinical implications

In routine practice, oral JAK inhibitors produced meaningful repigmentation for many patients with vitiligo; extending treatment beyond 6 months was associated with better response, and no severe adverse events were seen in this cohort.